FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation

Tyrosine kinase inhibitors (TKIs) targeting FLT3 have shown activity but when used alone have achieved limited success in clinical trials, suggesting the need for combination with other drugs. We investigated the combination of FLT3 TKIs (Gilteritinib or Sorafenib), with Venetoclax, a BCL-2 selectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Ruiqi, Li, Li, Nguyen, Bao, Seo, Jaesung, Wu, Min, Seale, Tessa, Levis, Mark, Duffield, Amy, Hu, Yu, Small, Donald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141515/
https://www.ncbi.nlm.nih.gov/pubmed/34024909
http://dx.doi.org/10.1038/s41392-021-00578-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141515/
https://www.ncbi.nlm.nih.gov/pubmed/34024909
http://dx.doi.org/10.1038/s41392-021-00578-4

Ejemplares similares